Resumen

Objectives: -Evaluate the efficacy of a novel, less-rigidly crosslinked, 15 mg/mL resilient, high-stretch HA filler injected subdermally for improving facial fine lines of the cheek. -Address concerns related to fine lines of the cheek, which develop due to ultraviolet exposure, dynamic expression, and aging. -Analyze existing treatments for static and dynamic facial fine lines, including laser resurfacing, retinoids, chemical peels, and fillers. -Investigate the potential of dynamic, adaptive HA fillers to improve skin quality and reduce fine lines while minimizing risks. Introduction: Fine lines on the cheeks develop due to UV exposure, facial expressions, aging-related loss of skin elasticity, and superficial fat depletion. These concerns are increasingly common among patients, especially as cosmetic treatments gain popularity. Current options, including laser resurfacing, retinoids, chemical peels, and fillers, improve skin texture but often lack dynamic properties for natural results. Our study evaluates a novel, 15 mg/mL resilient, high-stretch HA filler injected subdermally for improving radial cheek lines, aiming to enhance patient satisfaction. Materials / method: Subjects were enrolled from a cosmetic dermatology practice. Outcomes were assessed using photographs, Allergan Fine Lines Scale (AFLS) ratings (0-4) for facial lines, and FACE-Q Appraisal of Lines: Satisfaction of Skin (0-4). Total score improvements for skin quality were compared between baseline, 4 weeks, and 8 weeks post-treatment. The dynamic HA-based filler was injected in a grid pattern with 0.025-0.05cc administered subdermally at 0.5-1cm intervals across the malar and nasolabial cheek areas. Treatment occurred in two visits, 4-6 weeks apart, with final follow-up at 8 weeks. Results: Twenty subjects met inclusion and exclusion criteria. The average injection volume was 1.8±0.18 cc. AFLS scores showed significant improvement from baseline to 4 weeks after one treatment (3.4±0.2 vs. 3.2±0.2, p=0.049) and from baseline to 8 weeks after two treatments (3.4±0.2 vs. 2.35±0.1, p<0.01). FACE-Q scores improved significantly from baseline to 4 weeks (45.9±3 vs. 67.4±4.2, p=0.0004) and from baseline to 8 weeks (45.9±3 vs. 62±4.0, p=0.0034). No long-term adverse events were reported. Conclusion: In conclusion: Microdroplet injections using a 15 mg/mL resilient, high-stretch hyaluronic acid (HA) filler significantly enhance both patient-reported (FACE-Q) and physician-reported outcomes for radial cheek lines. The use of this dynamic HA filler leads to marked improvements in facial appearance and skin radiance with minimal side effects. This treatment approach has the potential to boost patient self-assurance and overall quality of life by effectively replenishing superficial support, reducing the visibility of radial cheek lines, and enhancing skin attractiveness.